Core Viewpoint - Beijing Beier Bioengineering Co., Ltd. has once again paused its IPO journey, marking the third attempt since 2020 without success [2][3] IPO Attempts - Beier Bio's IPO journey has been tumultuous, with multiple attempts since its first application in July 2020, which was withdrawn in February 2021. The company then shifted to the Shanghai Stock Exchange in October 2021, but this attempt also failed. In April 2025, it redirected its efforts to the Beijing Stock Exchange, where its IPO was accepted on June 30, but was halted three months later due to the need for updated financial reports [3][4] Fundraising Plans - The company plans to publicly issue up to 25 million shares, aiming to raise a total of approximately 537 million yuan, which will be allocated to the construction of an in vitro diagnostic reagent and instrument production base and a research and development center [4][5] Project Feasibility Concerns - Despite claiming to be a "national-level specialized and innovative small giant," the feasibility and return prospects of its fundraising projects are questioned due to tightening industry policies, increasing market competition, and rising tax burdens [4][6] Financial Performance - Beier Bio has experienced significant revenue fluctuations, with a 50.57% increase in revenue and a 237.21% increase in net profit in 2023, followed by a decline in both metrics in 2024, with revenue down 9.08% and net profit down 6.00% [7][8] Core Product Revenue Decline - The decline in revenue is primarily attributed to a drop in income from core product lines, particularly the respiratory pathogen detection series, which saw a 10.3% decrease in revenue from 2023 to 2024 [9][10] Market Competition and Risks - The in vitro diagnostic market is highly competitive, with major players like Roche and Abbott dominating. Beier Bio's lack of brand influence and market coverage raises concerns about its ability to maintain market share if competitors adopt aggressive pricing strategies [6][11] Tax Policy Impact - Starting in 2025, the company will face increased tax burdens as it transitions from a simplified tax method to a general tax method, significantly raising its tax costs and further squeezing profit margins [6][11] Technology Transition Challenges - The company heavily relies on traditional enzyme-linked immunosorbent assays and colloidal gold reagents, which are losing market share to newer technologies like chemiluminescence. If Beier Bio fails to adapt and innovate, it risks being outpaced by competitors [10][11]

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, with a focus on domestic market challenges and strong overseas growth opportunities [1][2][3][4]. Domestic Market Performance - The domestic market is under pressure due to policy impacts, but large-scale installations are ongoing, laying a foundation for long-term growth. In H1 2025, domestic revenue was 1.229 billion yuan, down 12.81% year-on-year, with reagent revenue decreasing by 18.96% and instrument revenue increasing by 18.18% [2]. - The company completed the installation of 774 units, with large machines accounting for 74.81% and coverage rates for tertiary hospitals at 47.6% and for top-tier hospitals at 63.5% [2]. Overseas Market Performance - The overseas market showed strong growth, with revenue reaching 0.952 billion yuan, up 19.57% year-on-year. The reagent business grew by 36.86% due to increased installation volumes, with 1,971 units sold, and high-end models making up 77.02% of sales [3]. Financial Performance and Profitability - The company increased its sales and R&D investments, leading to temporary pressure on profits due to a higher proportion of low-margin products. The overall gross margin decreased to 68.44%, down 4.17 percentage points, and the net profit margin fell to 35.29%, down 5.56 percentage points [4]. - The company expects revenue for 2025-2027 to be 4.888 billion, 5.625 billion, and 6.477 billion yuan, with year-on-year growth rates of 7.78%, 15.07%, and 15.16%, respectively. Net profits are projected to be 1.866 billion, 2.183 billion, and 2.571 billion yuan, with corresponding growth rates of 2.06%, 16.98%, and 17.79% [4].

Core Viewpoint - The company, Dirui Medical, is facing significant financial challenges, with a projected net loss of 22 million to 33 million yuan for the first half of 2025, marking its first half-year loss in 11 years since its listing, contrasting sharply with a profit of 165 million yuan in the same period last year [2][3] Financial Performance - The company reported a 11.63% decline in revenue and a 48.5% drop in net profit for the full year of 2024, with the fourth quarter showing a staggering 87.14% decrease in total revenue [4] - The net profit for 2024 was only 142 million yuan, with a significant cash flow reversal from a net cash inflow of 224 million yuan in the previous year to a net outflow of 295 million yuan, a decline of 231.29% [4] Asset Quality and Impairment - Dirui Medical attributed its losses to a decline in overall gross profit and a substantial increase in asset impairment losses, with a provision for asset impairment of 23.89 million yuan announced alongside the earnings forecast [3][4] Product Structure and Market Position - The company has a product structure imbalance, with reagent revenue accounting for only 48.51% and instrument revenue at 51.49%, contrasting with industry leaders where reagent revenue is significantly higher [5] - The decline in gross margins for both reagent and instrument products was noted, with reagent gross margin dropping from 75.42% to 70.06% and instrument gross margin from 33.99% to 24.26% [4][5] Competitive Landscape - Dirui Medical faces intense competition from both domestic players like Mindray and international giants such as Abbott and Sysmex, particularly in the blood cell analysis market [6] - The company’s BF series blood cell analyzers, while technically advanced, struggle with brand recognition and channel development, hindering market penetration [6] Strategic Response and Management Changes - The company has outlined measures to focus on increasing reagent sales and expanding into international markets, although these strategies will require time to yield results [7][8] - Recent management changes include the departure of four board members, with new candidates from the China Resources background proposed, raising questions about the new leadership's ability to navigate the company out of its current difficulties [9]

Investment Rating - The report gives a "Buy" rating for the company with a target price of 47.95 RMB per share, based on a 21x PE valuation for 2025 [4]. Core Insights - The company is a leading player in the domestic in vitro diagnostics industry, primarily focusing on immunodiagnostics. The implementation of centralized procurement is expected to accelerate the domestic production process and enhance market share through high-speed analyzers [2][32]. - The company is expanding its product offerings across multiple innovative business areas, including automated laboratory workflows, molecular diagnostics, and microbiological mass spectrometry, which are expected to drive future growth [2][3][58]. - The international market expansion is underway, with overseas sales projected to reach 286 million RMB in 2024, reflecting a year-on-year growth of 36.6% [3]. Summary by Sections Investment Logic - The centralized procurement led by Anhui Province is expected to boost the demand for the company's products, with successful bids in the first round of procurement [2]. - The high-throughput chemiluminescence immunoassay analyzer AutoLumo A6000 has a detection speed of 600 tests per hour, which will enhance the company's market share in high-end products [2][49]. Business Expansion - The company is actively developing automated laboratory workflows, molecular diagnostics, and microbiological mass spectrometry systems, which are anticipated to create new growth avenues [2][3][58]. - The Sikun2000 gene sequencer is expected to capture market share following the ban on foreign competitor sales in China [2][3]. Financial Forecast and Investment Advice - The projected net profits for 2025-2027 are 1.305 billion, 1.566 billion, and 1.884 billion RMB, respectively, with growth rates of 9%, 20%, and 20% [4]. - The company’s revenue is expected to grow from 4.471 billion RMB in 2024 to 7.081 billion RMB by 2027, with a compound annual growth rate of approximately 18.74% [8]. Market Trends - The domestic in vitro diagnostics market is expected to grow significantly, with the immunodiagnostics segment projected to reach 105.5 billion RMB by 2028, reflecting a compound annual growth rate of 19.1% [39][40]. - The company’s international sales have increased from 1.5% of total revenue in 2017 to an estimated 6.5% in 2024, indicating a growing focus on global markets [25][27]. Competitive Landscape - The company holds a market share of 4% in the domestic immunodiagnostics market, which is dominated by foreign brands, indicating significant potential for growth through domestic product enhancements and procurement policies [45][46].